The European in vitro diagnostics (IVD) market is projected to grow significantly, reaching USD 57 billion by 2035, up from USD 32 billion in 2024, with a compound annual growth rate of 5.4% during this period.
This growth reflects a shift in the role of diagnostic technologies, now seen as integral to clinical decision-making and public health strategies. The IVD sector encompasses a wide range of tools used for analyzing biological samples, which are crucial for diagnosing various health conditions, including infectious diseases and chronic illnesses. The increasing demand for early and cost-effective diagnostic solutions is driven by an aging population and a rising burden of chronic diseases.
Key factors propelling this market include a notable rise in infectious diseases, with the World Health Organization reporting a significant increase in measles cases in Europe. Additionally, advancements in next-generation sequencing technologies are enhancing disease detection capabilities. Public investments, such as the expansion of community diagnostic centers in the UK, further bolster the infrastructure for diagnostic testing across Europe.
As the market evolves, there is a clear trend toward personalized medicine, where diagnostic techniques are integrated into tailored treatment plans. This shift not only increases testing volumes but also broadens the market for IVD manufacturers. The competitive landscape is diverse, featuring both large multinational corporations and specialized firms, with strategic partnerships becoming increasingly important as companies navigate the complexities of regulatory compliance.